Show simple item record

dc.contributor.authorLee, S.
dc.contributor.authorVarano, J.
dc.contributor.authorFlexman, J.
dc.contributor.authorCheng, W.
dc.contributor.authorWatson, M.
dc.contributor.authorRossi, E.
dc.contributor.authorAdams, L.
dc.contributor.authorBulsara, M.
dc.contributor.authorPrice, Patricia
dc.identifier.citationLee, S. and Varano, J. and Flexman, J. and Cheng, W. and Watson, M. and Rossi, E. and Adams, L. et al. 2010. Decreased IP-10 and elevated TGFß1 levels are associated with viral clearance following therapy in patients with hepatitis C virus. Disease Markers. 28 (5): pp. 273-280.

The role of pro-fibrogenic cytokines in the outcome of infections with hepatitis C virus (HCV) and the response to treatment with pegylated interferon-alpha (pegIFNa) and ribavirin remains unclear. To address this issue, we assessed hepatic fibrosis and plasma markers pertinent to T-cell mediated fibrogenesis and inflammation at the start of treatment. Levels of soluble (s)CD30, interleukin-13 receptor alpha 2 (IL-13Ra2), total and active transforming growth factor-beta 1 (TGFß1), interleukin-18 (IL-18) and interferon-gamma inducible protein-10 (IP-10, CXCL10) were correlated with the severity of fibrosis and with treatment outcome using multiple logistic regression modelling. The Hepascore algorithm was confirmed as a marker of fibrosis, but was a poor predictor of treatment outcome. Inclusion of all immunological markers improved prediction based on Hepascore alone (p=0.045), but optimal prediction was achieved with an algorithm ("TIPscore") based on TGFß1 (total), IP-10, age, sex and HCV genotype (p=0.003 relative to Hepascore). Whilst this was only marginally more effective than predictions based on HCV genotype age and sex (p=0.07), it associates high TGFß1 and low IP-10 levels with a failure of therapy. © 2010 - IOS Press and the authors. All rights reserved.

dc.publisherHindawi Publishing Corporation
dc.titleDecreased IP-10 and elevated TGFß1 levels are associated with viral clearance following therapy in patients with hepatitis C virus
dc.typeJournal Article
dcterms.source.titleDisease Markers
curtin.departmentSchool of Biomedical Sciences
curtin.accessStatusFulltext not available

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record